CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Investigation

• Publication date

  2014-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI73048PMID 24911146PMCID PMC4071378
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

  2014cited by this paper
• EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

  2013cited by this paper
• Nodal signalling in embryogenesis and tumourigenesis.

  2013cited by this paper
• Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

  2013cited by this paper
• ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

  2013cited by this paper
• Nodal promotes invasive phenotypes via a Mitogen Activated Protein Kinase-dependent pathway

  2013cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012cited by this paper
• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  2012cited by this paper
• c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

  2012cited by this paper
• Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011influential reference
• BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

  2011cited by this paper
• MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement

  2011cited by this paper
• EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells.

  2011cited by this paper
• Expression and functional role of CRIPTO-1 in cutaneous melanoma

  2011cited by this paper
• TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Targeting the embryonic gene Cripto-1 in cancer and beyond

  2010cited by this paper
• Role of Src family kinases in acquired resistance to EGFR therapies in cancer

  2009cited by this paper
• Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

  2009cited by this paper
• Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy

  2009cited by this paper
• Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.

  2009cited by this paper
• The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

  2008influential reference
• CRIPTO3, a presumed pseudogene, is expressed in cancer.

  2008cited by this paper
• Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer

  2008cited by this paper
• Positive association of up‐regulated Cripto‐1 and down‐regulated E‐cadherin with tumour progression and poor prognosis in gastric cancer

  2008cited by this paper
• A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

  2008cited by this paper
• Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

  2007cited by this paper
• Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.

  2007cited by this paper
• MicroRNAs in disease and potential therapeutic applications.

  2007cited by this paper
• Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

  2007cited by this paper
• Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

  2006cited by this paper
• Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

  2006cited by this paper
• Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

  2006cited by this paper
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  2006cited by this paper
• Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

  2006cited by this paper
• Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.

  2006cited by this paper
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Cripto-1: an oncofetal gene with many faces.

  2005cited by this paper
• Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Cripto‐1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF‐7 breast cancer cells

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Cripto: a novel target for antibody-based cancer immunotherapy.

  2004cited by this paper
• Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

  2004cited by this paper
• A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src.

  2003cited by this paper
• Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells

  2002cited by this paper
• Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling

  2002cited by this paper
• Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms.

  2001cited by this paper
• Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues

  1996cited by this paper
• Taxol in the treatment of lung cancer.

  1993cited by this paper
• Taxol in the treatment of lung cancer.

  1993cited by this paper
• Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.

  1992cited by this paper
• Clinical investigation.

  1967cited by this paper

• The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer.

  2026cites this paper
• The Intricate Web of MicroRNAs in Modulating EGFR-TKI Resistance in Non-Small Cell Lung Cancer: A Comprehensive Review

  2025cites this paper
• Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance.

  2025cites this paper
• The interaction between ncRNAs and the EGFR signaling pathway in lung cancer

  2025cites this paper
• Advances in the study of Epithelial Mesenchymal Transition in cancer progression: Role of miRNAs.

  2025cites this paper
• Epigenetic code underlying EGFR-TKI resistance in non-small-cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies.

  2025cites this paper
• The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations

  2024influential citation
• Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer

  2024cites this paper
• DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma

  2024cites this paper
• Paeoniae radix overcomes resistance to EGFR-TKIs via aurora B pathway suppression in lung adenocarcinoma.

  2024cites this paper
• The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

  2023cites this paper
• Root Extract of Trichosanthes kirilowii Suppresses Metastatic Activity of EGFR TKI-Resistant Human Lung Cancer Cells by Inhibiting Src-Mediated EMT

  2023cites this paper
• PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

  2022cites this paper
• Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

  2022cites this paper
• Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer

  2022cites this paper
• CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer

  2022cites this paper
• Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy

  2021cites this paper
• EMT‐associated microRNAs and their roles in cancer stemness and drug resistance

  2021influential citation
• Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line

  2021cites this paper
• Whence CRIPTO: The Reemergence of an Oncofetal Factor in ‘Wounds’ That Fail to Heal

  2021cites this paper
• Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications

  2021cites this paper
• A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

  2021cites this paper
• Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models

  2021cites this paper
• Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer

  2021cites this paper
• Conditional reprogramming: next generation cell culture

  2020cites this paper
• Generation of Osimertinib-Resistant Cells from EGFR L858R/T790M Mutant NSCLC Cell Line.

  2020cites this paper
• Characterizing heterogeneity of non‐small cell lung tumour microenvironment to identify signature prognostic genes

  2020cites this paper
• A Multidisciplinary Review of the Roles of Cripto in the Scientific Literature Through a Bibliometric Analysis of its Biological Roles

  2020cites this paper
• Conditional cell reprogramming for modeling host‐virus interactions and human viral diseases

  2020cites this paper
• Structure and Characterization of a Covalent Inhibitor of Src Kinase

  2020cites this paper
• Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.

  2020cites this paper
• Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line

  2020cites this paper
• Acquired Resistance in Lung Cancer

  2020cites this paper
• Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis.

  2020cites this paper
• Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks

  2019cites this paper
• High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.

  2019cites this paper
• Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.

  2019cites this paper
• Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs

  2019cites this paper
• MicroRNA in Lung Cancer Metastasis

  2019cites this paper
• Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance

  2019cites this paper
• novel angiogenic peptides in breast cancer

  2019cites this paper
• Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

  2019influential citation
• 1 Intrinsic resistance to EGFR-tyrosine kinase 2 inhibitors in EGFR-mutant non-small cell lung 3 cancer : differences and similarities with acquired 4 resistance 5

  2019influential citation
• Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.

  2019cites this paper
• Circular RNA circ‐CMPK1 contributes to cell proliferation of non‐small cell lung cancer by elevating cyclin D1 via sponging miR‐302e

  2019cites this paper
• Collagen type I induces EGFR‐TKI resistance in EGFR‐mutated cancer cells by mTOR activation through Akt‐independent pathway

  2018cites this paper
• Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.

  2018cites this paper
• CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma

  2018cites this paper
• Role of miR-23a/Zeb1 negative feedback loop in regulating epithelial-mesenchymal transition and tumorigenicity of intraocular tumors

  2018cites this paper
• Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

  2018cites this paper
• Expansion of airway basal epithelial cells from primary human non‐small cell lung cancer tumors

  2018cites this paper
• Src promotes EGF‐induced epithelial‐to‐mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT

  2018cites this paper
• 上皮间质转化在非小细胞肺癌EGFR-TKIs耐药中的研究进展

  2018cites this paper
• Targeting Nodal and Cripto-1: perspectives inside dual potential theranostic cancer biomarkers.

  2018cites this paper
• Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage

  2018cites this paper
• High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.

  2018cites this paper
• Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.

  2018cites this paper
• Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

  2018cites this paper
• A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

  2018cites this paper
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

  2018cites this paper
• Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.

  2018cites this paper
• Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

  2017cites this paper
• Clinical significance of cripto-1 expression in lung adenocarcinoma

  2017cites this paper
• Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer

  2017cites this paper
• Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer

  2017cites this paper
• The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.

  2017cites this paper
• SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

  2017cites this paper
• Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrc

  2017cites this paper
• T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

  2017cites this paper
• Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.

  2016cites this paper
• Mechanisms of resistance to EGFR-targeted drugs: lung cancer

  2016cites this paper
• miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway

  2016cites this paper
• Resisting Resistance: Targeted Therapies in Lung Cancer.

  2016cites this paper
• Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer

  2016cites this paper
• Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer

  2016cites this paper
• The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

  2016cites this paper
• Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions

  2016cites this paper
• Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

  2016cites this paper
• Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs.

  2016cites this paper
• Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.

  2015cites this paper
• Mechanisms of resistance to EGFR tyrosine kinase inhibitors

  2015cites this paper
• EMT, CTCs and CSCs in tumor relapse and drug-resistance

  2015cites this paper
• Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

  2015cites this paper
• Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.

  2015cites this paper
• Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.

  2015cites this paper
• Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.

  2015cites this paper
• MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview.

  2015cites this paper
• CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities

  2015influential citation
• MicroRNAs and Gastrointestinal Stromal Tumor.

  2015cites this paper
• MicroRNAs as the fine-tuners of Src oncogenic signalling.

  2015cites this paper
• Refining the treatment of NSCLC according to histological and molecular subtypes

  2015cites this paper
• Genetic modifiers of EGFR dependence in non-small cell lung cancer

  2014cites this paper
• Cripto-1 as a novel therapeutic target for triple negative breast cancer

  2014cites this paper
• MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use

  2014cites this paper